Role of Renal Sympathetic Nerves in GLP-1 (Glucagon-Like Peptide-1) Receptor Agonist Exendin-4-Mediated Diuresis and Natriuresis in Diet-Induced Obese Rats

被引:9
|
作者
Liu, Xuefei [1 ]
Patel, Kaushik P. [2 ]
Zheng, Hong [1 ]
机构
[1] Univ South Dakota, Div Basic Biomed Sci, Sanford Sch Med, Vermillion, SD 57069 USA
[2] Univ Nebraska Med Ctr, Dept Cellular & Integrat Physiol, Omaha, NE USA
来源
JOURNAL OF THE AMERICAN HEART ASSOCIATION | 2021年 / 10卷 / 21期
基金
美国国家卫生研究院;
关键词
glucagon-like peptide-1; neprilysin; obesity; renal nerve; sodium retention; BLOOD-PRESSURE; HEART-FAILURE; SODIUM-EXCRETION; HYPERTENSION; NEPRILYSIN; LIRAGLUTIDE; EXPRESSION; IMPACT; INJURY;
D O I
10.1161/JAHA.121.022542
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The gut-derived hormone GLP-1 (glucagon-like peptide-1) exerts beneficial effects against established risk factors for chronic kidney disease. GLP-1 influences renal function by stimulating diuresis and natriuresis and thus lowering arterial blood pressure. The role of the sympathetic nervous system has been implicated as an important link between obesity with elevated arterial pressure and chronic kidney disease. The primary aim of this study was to determine the contribution of renal sympathetic nerves on intrapelvic GLP-1-mediated diuresis and natriuresis in high-fat diet (HFD)-induced obese rats. Methods and Results Obesity was induced in rats by HFD for 12 weeks, followed by either surgical bilateral renal denervation or chronic subcutaneous endopeptidase neprilysin inhibition by sacubitril for a week. Diuretic and natriuretic responses to intrapelvic administration of the GLP-1R (GLP-1 receptor) agonist exendin-4 were monitored in anesthetized control and HFD rats. Renal GLP-1R expression and neprilysin expression and activity were measured. The effects of norepinephrine on the expression of GLP-1R and neprilysin in kidney epithelial LLC-PK1 cells were also examined. We found that diuretic and natriuretic responses to exendin-4 were significantly reduced in the HFD obese rats compared with the control rats (cumulative urine flow at 40 minutes, 387 +/- 32 versus 650 +/- 65 mu L/gkw; cumulative sodium excretion at 40 minutes, 42 +/- 5 versus 75 +/- 10 mu Eq/gkw, P<0.05). These responses in the HFD rats were restored after ablation of renal nerves (cumulative urine flow at 40 minutes, 625 +/- 62 versus 387 +/- 32 mu L/gkw; cumulative sodium excretion at 40 minutes, 70 +/- 9 versus 42 +/- 5 mu Eq/gkw, P<0.05). Renal denervation induced significant reductions in arterial pressure and heart rate responses to intrapelvic GLP-1 in the HFD rats. Renal denervation also significantly increased the GLP-1R expression and reduced neprilysin expression and activity in renal tissues from the HFD rats. Chronic subcutaneous neprilysin inhibition by sacubitril increased GLP-1-induced diuretic and natriuretic effects in the HFD rats. Finally, exposure of the renal epithelial cells to norepinephrine in vitro led to downregulation of GLP-1R expression but upregulation of neprilysin expression and activity. Conclusions These results suggest that renal sympathetic nerve activation contributes to the blunted diuretic and natriuretic effects of GLP-1 in HFD obese rats. This study provides significant novel insight into the potential renal nerve-neprilysin-GLP-1 pathway involved in renal dysfunction during obesity that leads to hypertension.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Endothelial GLP-1 (Glucagon-Like Peptide-1) Receptor Mediates Cardiovascular Protection by Liraglutide In Mice With Experimental Arterial Hypertension
    Helmstaedter, Johanna
    Frenis, Katie
    Filippou, Konstantina
    Grill, Alexandra
    Dib, Mobin
    Kalinovic, Sanela
    Pawelke, Franziska
    Kus, Kamil
    Kroeller-Schoen, Swenja
    Oelze, Matthias
    Chlopicki, Stefan
    Schuppan, Detlef
    Wenzel, Philip
    Ruf, Wolfram
    Drucker, Daniel J.
    Muenzel, Thomas
    Daiber, Andreas
    Steven, Sebastian
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2020, 40 (01) : 145 - 158
  • [22] Glucagon-like peptide-1 (GLP-1) receptor agonists for weight management: A review for the gynecologic oncologist
    Riedinger, Courtney J.
    Sakach, Julia
    Maples, Jill M.
    Fulton, Jessica
    Chippior, Jessica
    O'Donnell, Benjamin
    O'Malley, David M.
    Chambers, Laura M.
    GYNECOLOGIC ONCOLOGY, 2024, 190 : 1 - 10
  • [23] Glucagon-like peptide-1 (GLP-1) receptor agonist prevents development of tolerance to anti-anxiety effect of ethanol and withdrawal-induced anxiety in rats
    Ajaykumar N. Sharma
    Ashish Pise
    Jay N. Sharma
    Praveen Shukla
    Metabolic Brain Disease, 2015, 30 : 719 - 730
  • [24] Glucagon-like peptide-1 (GLP-1) receptor agonist prevents development of tolerance to anti-anxiety effect of ethanol and withdrawal-induced anxiety in rats
    Sharma, Ajaykumar N.
    Pise, Ashish
    Sharma, Jay N.
    Shukla, Praveen
    METABOLIC BRAIN DISEASE, 2015, 30 (03) : 719 - 730
  • [25] ALBIGLUTIDE Glucagon-Like Peptide GLP-1 Receptor Agonist Treatment of Type 2 Diabetes
    Rosenstock, Julio
    Stewart, Murray W.
    DRUGS OF THE FUTURE, 2010, 35 (09) : 701 - 712
  • [26] Indirect Effects of Glucagon-Like Peptide-1 Receptor Agonist Exendin-4 on the Peripheral Circadian Clocks in Mice
    Ando, Hitoshi
    Ushijima, Kentarou
    Fujimura, Akio
    PLOS ONE, 2013, 8 (11):
  • [27] Glucagon-like peptide-1 receptor agonist exendin-4 mitigates lipopolysaccharide-induced inflammatory responses in RAW264.7 macrophages
    Lu, Canrong
    Xie, Tianyu
    Guo, Xin
    Wu, Di
    Li, Shuo
    Li, Xiongguang
    Lu, Yixun
    Wang, Xinxin
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2019, 77
  • [28] The Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Liraglutide Regulates Sirtuin-i-Mediated Neutrophil Extracellular Traps to Improve Diabetes-Induced Bone Metabolism Imbalance
    Zhong, Shuai
    Huang, Liangzhi
    Lin, Tingting
    Li, Yanyan
    Deng, Bin
    Kong, Dezhi
    Liao, Zhanlin
    Huang, Zugui
    IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH, 2024, 23 (01):
  • [29] Characterization of glucagon-like peptide-1 (GLP-1) agonist exposures reported to a single United States poison center
    Muschler, Karen
    Muschalek, Rachael
    Hoyte, Christopher
    CLINICAL TOXICOLOGY, 2025, 63 (02) : 133 - 136
  • [30] Plasma glucagon-like peptide-1 (GLP-1) responses to duodenal fat and glucose infusions in lean and obese men
    Feinle, C
    Chapman, IM
    Wishart, J
    Horowitz, M
    PEPTIDES, 2002, 23 (08) : 1491 - 1495